NORTH CHICAGO, Ill., July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development and chief scientific officer. In this position, Dr. Thakkar will lead the company's global R&D organization of more than 14,000 team members across all phases of discovery and development, including therapeutics and aesthetics.
"Dr. Thakkar is a physician by training with a deep commitment to innovation and patient care," said Rob Michael, chief executive officer, AbbVie. "He has an excellent track record in building new capabilities, forging strategic partnerships and advancing our clinical programs to bring medicines and solutions to patients as quickly as possible. As AbbVie's chief scientific officer, Dr. Thakkar will continue to build momentum across discovery and all stages of development to fully realize the potential of our diverse pipeline. He has the right vision, skills and experience to lead our R&D organization."
"I am excited to assume these new responsibilities for the R&D organization at AbbVie," said Roopal Thakkar, M.D, executive vice president, research & development and chief scientific officer, AbbVie. "Our pipeline of more than 90 drug and device programs presents a significant opportunity to ensure AbbVie's growth well into the next decade. I am confident that our outstanding R&D team will continue to deliver critical innovation and it's my privilege to lead this organization as we take on the most challenging health issues for patients."
Thomas J. Hudson, M.D., who currently serves as AbbVie's senior vice president, chief scientific officer, global research, will retire from AbbVie. Dr. Hudson joined AbbVie in 2016 overseeing oncology discovery and early development before assuming the role of vice president, discovery research. He was appointed to the role of chief scientific officer in 2019. Over the past eight years, Dr. Hudson helped shape AbbVie's approach to early-stage science, built precision medicine capabilities, guided many scientific partnerships and developed data strategies to accelerate drug discovery and development.
About Roopal Thakkar, M.D.
Dr. Roopal Thakkar serves as executive vice president, research & development, chief scientific officer at AbbVie. In this role, he leads the company's R&D organization of more than 14,000 team members around the world and is focused on driving pipeline advancement across therapeutics and aesthetics. Dr. Thakkar is also responsible for the six major R&D centers of excellence located across the United States, Germany and Japan.
He joined Abbott/AbbVie in 2003 as part of the Physician Development Program. Since then, he has held several positions in clinical development, including group project director, immunology, as well as vice president, global regulatory affairs where he was responsible for driving industry-leading regulatory submissions to health authorities around the world.
In 2019, Dr. Thakkar assumed the role of vice president, global regulatory affairs and R&D quality assurance and in 2022 he was appointed to the role of senior vice president, development and regulatory affairs and chief medical officer.
In 2023, Dr. Thakkar was appointed senior vice president, chief medical officer, global therapeutics. In this role, he led the organization through many strategic acquisitions and propelled and delivered clinical development programs across immunology, oncology, neuroscience, eye care and specialty.
Prior to joining AbbVie, he completed training in internal medicine and was a clinical fellow at the University of Alabama, Birmingham, and at Wake Forest University School of Medicine. Dr. Thakkar received his bachelor's degree in cellular and molecular biology from the University of Michigan and his M.D. from the Wayne State University School of Medicine.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
SOURCE AbbVie
